← Oncology Approval Tracker

FDA DECISION ·

Tagrisso

osimertinib · AstraZeneca

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable stage III non-small cell lung cancer, EGFR exon 19 deletion or exon 21 L858R on an FDA-approved test, and no progression during or after concurrent or sequential platinum chemoradiation.

LAMPGEN ANALYSIS

Why it matters

The LAURA-based indication adds EGFR-directed treatment after definitive chemoradiation for a molecularly selected group.

What research teams should watch

Route molecular results to the radiation team, and document restaging and evaluation of respiratory symptoms before starting.

PRIMARY RECORDS

Sources